MedTrace Logo

Palliative Lattice Stereotactic Body Radiotherapy (SBRT)

NCT04133415 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-11-22

Study results available
· View outcomes & findings →

Summary

Standard palliative radiotherapy regimens may provide limited durability of response in large tumors. Thus, there is a clinical need for a new approach. The Lattice SBRT approach will deliver 20 Gy in 5 fractions with partial volume simultaneous integrated boosts to 66.7 Gy. This is hypothesized to improve symptom response, local control, and better prime the tumor microenvironment for immune response compared with standard palliative radiotherapy doses. It is also hypothesized that this will be associated with less toxicity than the traditional homogenous SBRT plan delivered to a large tumor. Blood will be collected before and after Lattice SBRT for evaluation of the peripheral blood immune microenvironment.

Conditions

  • Cancer
  • Palliative Radiotherapy

Interventions

RADIATION

Lattice stereotactic body radiation therapy

-As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed

PROCEDURE

Peripheral blood

-Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Matthew Spraker, M.D., Ph.D. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2020-12-14
Completion
2020-12-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04133415 on ClinicalTrials.gov